Market Voices: Lilly's new obesity drug, Bessent, EQT's robotics move
Source: SeekingAlpha
2025-12-11 13:25:12 ET
More on Eli Lilly, EQT AB (publ)
- Eli Lilly: Retatrutide Justifies Hype With Best Weight Loss Data Yet - I'm Sold
- Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk
- Mounjaro In China: Assessing Market Potential And Risks
- Lilly rises on “best-in-class” data for new weight loss therapy
- Lilly succeeds in late-stage trial for next-gen weight loss therapy
Read the full article on Seeking Alpha
For further details see:
Market Voices: Lilly's new obesity drug, Bessent, EQT's robotics move
EQT AB
NASDAQ: EQBBF
EQBBF Trading
0.0% G/L:
$31.50 Last:
7,861 Volume:
$31.50 Open:
